No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
No Data
No Data
No Data
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Yahoo FinanceMar 27 20:42
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
Yahoo FinanceMar 21 20:41
Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, tod
GlobeNewswireNov 16, 2021 23:02
No Data
No Data